Scientists from the Icahn School of Medicine at Mount Sinai, Eli Lilly and Company, and Sema4 released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

These findings could pave the way for streamlined drug discovery, particularly for diseases such as schizophrenia that have seen little therapeutic innovation.